MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a crucial role in regulating gene expression. Several companies are advancing candidates relying on miRNAs in 2024, with potential applications in disease diagnosis and treatment. Companies such as aceRNA Technologies, ARTHEx Biotech, and Transcode Therapeutics are developing innovative miRNA-based therapeutics for various diseases, including cancer, cardiovascular…
Gene therapy has emerged as a transformative approach in modern medicine, offering a potential cure for a wide array of genetic disorders. By introducing, modifying, or repairing genetic material within a patient’s cells, gene therapy aims to rectify underlying genetic defects, thereby treating or preventing disease. The field has witnessed significant milestones, with several gene…
The biotech industry is witnessing a surge in the development of bispecific antibodies, a type of targeted therapy that can deliver two-in-one treatments to patients with cancer and other diseases. Several companies, including Adaptin Bio, Akeso, AP Biosciences, Candid Therapeutics, Summit Therapeutics, and Zenas BioPharma, are working on various bispecific antibody candidates, some of which…
Eight biotech companies are making significant strides in breast cancer treatment, with innovative approaches and therapies showing promise in clinical trials. Arvinas, BioNTech, Carrick Therapeutics, Context Therapeutics, Hummingbird Bioscience, Oncolytics Biotech, Olema Pharmaceuticals, and Relay Therapeutics are among the companies pushing the boundaries of cancer treatment, offering new hope for patients and their families. In…
The biotech industry is witnessing a surge in the development of exosome therapy companies, which are harnessing the potential of these tiny vesicles to treat a range of diseases, including cancer, neurological disorders, and inflammatory diseases. With several companies advancing their candidates through clinical trials, the global exosome therapeutics market is expected to grow significantly…
Cystic fibrosis is a debilitating genetic disorder that affects nearly 40,000 children and adults in the US. Recent advancements in biotechnology have led to the development of innovative treatments, including gene therapies and CFTR modulators. Companies like Enterprise Therapeutics, Krystal Biotech, Recode Therapeutics, Sionna Therapeutics, and Vertex Pharmaceuticals are at the forefront of this research,…
A recent surge in interest in T cell engagers, a type of antibody engineered to redirect the immune system’s T cells to recognize and kill cancer cells, suggests that this field is set to take off. Several biotech companies have launched specifically to develop these medicines, and big names in the industry are investing in…
The biotech industry is witnessing a surge in the development of GPCR (G protein-coupled receptor) therapies, with eight promising biotechs acquiring funding to fortify their pipelines. These biotechs are working on various GPCR-targeted drugs to address numerous diseases, including neuropathic pain, cancer, and metabolic disorders. The market for GPCR drugs is expected to grow significantly,…
Multiple sclerosis is a chronic disease of the central nervous system that affects nearly one million people in the U.S. alone. Biotech companies are working to expand therapeutic options for the disease, which is currently treated with disease-modifying drugs. Several companies, including Biogen, Immunic Therapeutics, Kyverna Therapeutics, Progentos Therapeutics, TG Therapeutics, and Zenas BioPharma, are…
Nanotechnology is transforming the healthcare industry with its potential to revolutionize drug delivery, diagnostics, and treatment of various diseases. Eight companies, including Sona Nanotech, Nanobiotix, and ARIZ Precision Medicine, are at the forefront of this revolution, developing innovative nanotechnology-based solutions for cancer treatment, autoimmune diseases, and other conditions. These companies are leveraging nanotechnology to create…
